Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, intermediate or good responders to first-line gefitinib. Clin...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Bria, Emilio, Pilotto, Sara, Amato, Eliana, Fassan, Matteo, Novello, Silvia, Peretti, Umberto, Vavalà, Tiziana, Kinspergher, Stefania, Righi, Luisella, Santo, Antonio, Brunelli, Matteo, Corbo, Vincenzo, Giglioli, Eliana, Sperduti, Isabella, Milella, Michele, Chilosi, Marco, Scarpa, Aldo, Tortora, Giampaolo
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Clinical Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494974/
https://ncbi.nlm.nih.gov/pubmed/25904052
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki